The FDA has accepted for priority review the biologics license application for odronextamab to treat adults with relapsed/refractory FL or DLBCL whose disease has progressed after at least 2 prior systemic therapies.
This year’s Nobel Prize in physiology or medicine has been awarded to 2 scientists who laid the groundwork for the mRNA research that made COVID-19 vaccines possible.
Breast Cancer Awareness Month promotes education on testing and detecting breast cancer early. This means understanding breast cancer symptoms, and how the disease progresses by stage. Does the staging of breast cancer affect symptoms?
For the first time since 2019, congressional gridlock is poised to temporarily shut down big parts of the federal government, including many health programs.
Seeking the right treatment for the right patient at the right time By PRI Healthcare Solutions At the beginning of 2023, the American Cancer Society annual report on prostate cancer took a page from A Tale of Two Cities: It was the best of times, it was the worst of times … it was the…
Researchers are evaluating the effects of adding atezolizumab to adjuvant treatment with trastuzumab emtansine in patients with HER2-positive breast cancer.
Patients with metastatic breast cancer who receive alpelisib in clinical practice have higher rates of hyperglycemia than patients who receive the drug in clinical trials, a new study suggests.
Researchers are conducting a phase 3 trial to compare Dato-DXd, with or without durvalumab, to investigator’s choice of treatment in patients with TNBC.
Privately-insured cancer patients living in states with restrictive telehealth policies were less likely to use telehealth in 2020 and 2021, a study showed.
Surgery to remove the primary tumor does not prolong overall survival in most patients with de novo metastatic breast cancer, a meta-analysis suggests.
Comparing Medicare Part D plans can reduce financial toxicity associated with the use of oral androgen inhibitors in patients with advanced prostate cancer, a study suggests.
Breast cancer patients without axillary lymph node involvement who have tumors no larger than 2 cm can safely forgo axillary surgery, a phase 3 trial suggests.
As currently defined, biochemical recurrence after surgery or radiation is not a reliable predictor of the risk of death from prostate cancer, investigators say.
First-line treatment with dabrafenib and trametinib can improve outcomes, when compared to standard chemotherapy, in children with BRAFV600-mutated low-grade glioma, a phase 2 trial suggests.
Prostate cancer patients treated with radiotherapy have a higher risk of developing and dying from bladder cancer or lung cancer than patients treated with radical prostatectomy alone, a study suggests.
Researchers have validated previously identified prognostic factors for pleural mesothelioma and identified “room for improvement” when predicting overall survival in this patient population.
Final results from the DREAMM-2 trial suggest that belantamab mafodotin produces durable responses in patients with relapsed/refractory multiple myeloma.
The FDA has accepted for priority review the supplemental new drug application for belzutifan to treat adults with advanced renal cell carcinoma who previously received immune checkpoint and anti-angiogenic therapies.
Taking adjuvant endocrine therapy for 7 to 8 years is likely sufficient for maximal disease-free survival benefits among most postmenopausal women with HR+ breast cancer, according to researchers.
Breakthroughs in targeted therapy and immunotherapy are partly responsible for the recent decline in US cancer deaths, according to the AACR Cancer Progress Report 2023.
Researchers are evaluating whether a breath test can detect malignant pleural mesothelioma in patients with asbestos exposure, and early results suggest it may be possible.
Experts have recommended that, for patients with cancer-related pain who are using nonmedical stimulants, opioids should be continued, monitoring should be increased, and tapering should be avoided.
US patients with lung cancer have a higher burden of death from COVID-19 than the general population, and this has been the case since the omicron variant became dominant, data suggest.
Perioperative durvalumab does not adversely impact surgical outcomes in patients with resectable non-small cell lung cancer, results from the AEGEAN trial suggest.
Adding nimotuzumab to treatment with gemcitabine improves survival outcomes in patients with KRAS wild-type advanced pancreatic cancer, a phase 3 trial suggests.
First-line treatment with serplulimab plus chemotherapy improves survival over chemotherapy alone in patients with advanced squamous NSCLC, a phase 3 trial suggests.
Osimertinib and chemotherapy is more effective than osimertinib alone as first-line treatment for patients with EGFR-mutant, advanced NSCLC, phase 3 data suggest.